Trials
Search / Trial NCT06444607

Hereditary Pheochromocytoma Assessment of Tumour Immunologies

Launched by RADBOUD UNIVERSITY MEDICAL CENTER · May 30, 2024

Trial Information

Current as of February 12, 2025

Recruiting

Keywords

Pheochromocytoma Paraganglioma Tumor Microenvironment Innate Immunity

ClinConnect Summary

This clinical trial is studying how the immune system relates to two types of tumors called pheochromocytomas and paragangliomas, which can be hereditary (passed down in families). The researchers want to understand how the immune system behaves differently in people who have these tumors due to genetic factors compared to those who don’t. They will also look at how the immune system changes as the tumor develops in those with a hereditary predisposition. By comparing these findings with a group of people who don’t have these tumors, the researchers hope to discover new treatments that target the immune system.

To participate in this trial, you need to be at least 18 years old and either newly diagnosed with pheochromocytoma or paraganglioma, or have a genetic mutation that increases your risk for developing these tumors. Participants will be asked to share information about their health and may undergo tests to help researchers learn more about the immune system’s role in these conditions. It’s important to note that if you are currently pregnant, breastfeeding, or have certain other health issues, you may not be eligible for this study. Overall, the goal is to gain valuable insights that could lead to better treatments for these tumors.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Part I:
  • Newly diagnosed patients with PPGL or newly diagnosed patients with (metastatic) PPGL recurrence.
  • OR patients with mutations which predispose for the development of PPGL.
  • Aged \> 18 years.
  • Part II:
  • Confirmed PPGL on pathology.
  • Aged \> 18 years.
  • Exclusion Criteria:
  • Unable to provide informed consent.
  • Active inflammatory or infectious comorbidities.
  • Other malignancies which are under active treatment (except for basal cell carcinoma, other in situ carcinomas).
  • Using medication interfering with the immune system
  • Pregnancy or breastfeeding
  • A self-reported alcohol consumption of \>21 units per week

Trial Officials

Margo Dona, PhD

Principal Investigator

Radboud University Medical Center

Henri Timmers, M.D. PhD

Principal Investigator

Radboud University Medical Center

Romana Netea-Maier, M.D. PhD

Principal Investigator

Radboud University Medical Center

Marieke de Laat, M.D. PhD

Principal Investigator

Radboud University Medical Center

About Radboud University Medical Center

Radboud University Medical Center is a leading academic medical institution located in Nijmegen, the Netherlands, dedicated to advancing healthcare through innovative research and education. As a prominent sponsor of clinical trials, Radboud UMC leverages its multidisciplinary expertise to conduct high-quality research that aims to improve patient outcomes and enhance medical knowledge. The center is committed to ethical standards and regulatory compliance, fostering collaboration among researchers, healthcare professionals, and patients to translate scientific discoveries into effective clinical applications. With a focus on personalized medicine and cutting-edge technologies, Radboud University Medical Center plays a pivotal role in shaping the future of healthcare through its rigorous clinical trial initiatives.

Locations

Nijmegen, Gelderland, Netherlands

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0